Hofbauer J, Zechner O
Department of Urology, University of Vienna Medical School, Austria.
Eur Urol. 1988;15(3-4):227-9. doi: 10.1159/000473439.
The beneficial effect of allopurinol treatment in metaphylaxis of hyperuricosuric calcium oxalate lithiasis has been analyzed in a retrospective study covering 10 years. 83 patients with hyperuricosuric calcium oxalate lithiasis (48 recurrent stone formers, 35 patients with a single stone episode) were treated with 300 mg allopurinol for 33.1 +/- 11.5 months. Subsequently, each patient was controlled for 43.9 +/- 27 months without therapy. The overall relapse rate was 28.9% but there is no statistically significant difference between treatment with and without allopurinol (Mann-Whitney: p = 0.16). The only striking difference was the fact that, with one exception, stone relapses occurred only in the group of recurrent stone formers, whereas the group with single stone formation seemed to be at a clearly decreased risk for stone recurrence during follow-up. This would suggest that factors other than those investigated in this study are responsible for the phenomenon of recurrent stone formation.
在一项为期10年的回顾性研究中，分析了别嘌醇治疗对高尿酸尿草酸钙结石病预防的有益效果。83例高尿酸尿草酸钙结石病患者（48例复发性结石形成者，35例单发结石患者）接受300mg别嘌醇治疗33.1±11.5个月。随后，对每位患者进行43.9±27个月的无治疗观察。总体复发率为28.9%，但接受别嘌醇治疗和未接受别嘌醇治疗之间无统计学显著差异（曼-惠特尼检验：p = 0.16）。唯一显著的差异是，除1例例外，结石复发仅发生在复发性结石形成者组，而单发结石组在随访期间结石复发风险似乎明显降低。这表明，本研究未调查的因素是复发性结石形成现象的原因。
